Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: sorrentotherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2022 | $5.00 | Overweight | Cantor Fitzgerald |
| 8/9/2021 | $30.00 → $26.00 | Buy | HC Wainwright & Co. |
Cantor Fitzgerald initiated coverage of Sorrento Therapeutics with a rating of Overweight and set a new price target of $5.00
HC Wainwright & Co. reiterated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $26.00 from $30.00 previously
B. Riley Securities initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $26.00
Alliance Global Partners initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $35
Alliance Global Partners initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $35
8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)
8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)
8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)
8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)
8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)
8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)
8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)
10-Q - Sorrento Therapeutics, Inc. (0000850261) (Filer)
8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)
NT 10-Q - Sorrento Therapeutics, Inc. (0000850261) (Filer)
SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento's chapter 11 case, which was filed on February 13, 2023. The financing will provide Sorrento with immediate liquidity so that it can continue operating its business as usual during its chapter 11 case. A hearing for final approval of
SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an IRS Form 8937 (the "Form 8937") to supplement its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company ("Scilex") previously held by Sorrento. The Form 8937 has been filed with the Internal Revenue Service and Sorrento expects to send copies of the form in the coming days to brokerage firms, banks, dealers and similar organizations to whom a dividend confirmation had previously been distr
SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an update to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the "Dividend Stock"). The update to the FAQs provides notice regarding the no lien code added on Scilex (NASDAQ:SCLX) common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed therein that a
SAN DIEGO, Feb. 16, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted approval of Sorrento's employee wages motion and interim approval of its cash management motion, in connection with Sorrento's chapter 11 petition, which was filed on February 13, 2023. Sorrento expects to seek approval of other customary "first day" motions in the coming days.
SAN DIEGO and PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements: Henry Ji, Ph.D., Chairman and Chief Executive Officer of Sorrento, commented: "Today, Sorrento Therapeutics, Inc. and its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc. ("Scintilla"), commenced voluntary proceedings under Chapter 11 of
PALO ALTO, Calif., Feb. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that its first virtual-only Annual Meeting of Stockholders (the "Meeting") is scheduled to be held on April 6, 2023 at 9AM PST. Scilex also announced that its Board of Directors has set the close of business on March 6, 2023 as the record date (the "Record Date") for determining stockholders entitled to notice of, and to
SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today distributed dividend confirmation statements to 146 brokerage firms regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))) held by Sorrento. These statements, which contain the account numbers and amount of Scilex dividend shares, were previously mailed out by Continental Stock Transfer & Trust Company. The dividend confirmation statements are being distributed on behalf of Sorrento and Scilex to notify each brokerage firm of Sorrento's previously announced stock dividend (the "Dividend") consisting of an a
SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a supplement to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation's removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed
PALO ALTO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a supplement to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation's removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento's stockholders and
SAN DIEGO, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The FAQs address questions regarding the details of the dividend, including the record date, payment date, dividend ratio, distribution of the shares of Scilex common stock, how Sorrento stockholders can obtain certain information regarding the dividend, CUSIP information for Scilex common stock, and transfer restrictions on the divide
SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SC 13G - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SC 13G - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)
SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an IRS Form 8937 (the "Form 8937") to supplement its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company ("Scilex") previously held by Sorrento. The Form 8937 has been filed with the Internal Revenue Service and Sorrento expects to send copies of the form in the coming days to brokerage firms, banks, dealers and similar organizations to whom a dividend confirmation had previously been distr
SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an update to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the "Dividend Stock"). The update to the FAQs provides notice regarding the no lien code added on Scilex (NASDAQ:SCLX) common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed therein that a
SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a supplement to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation's removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed
PALO ALTO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a supplement to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation's removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento's stockholders and
COVISTIX is a highly sensitive and rapid antigen detection test for SARS-CoV-2 and its major variants of concern (VOCs), including the Omicron variant.COVISTIX has an enhanced sensitivity in detecting the Omicron variant with a more than 10-fold lower limit of detection (LoD) as compared to that of the original SAR-CoV-2 strain.COVISTIX has been approved for emergency use and is on the market in Brazil and Mexico, and is CE marked for sale in Europe for professional point-of-care use.In response to increasing product demand, Sorrento has invested and becomes a majority owner with an option to acquire 100% of FortuneBio, a diagnostic product manufacturer with dozens of approved diagnostic pro
Virex Health, Inc. is a Boston, Massachusetts company that has developed a powerful, broadly applicable at-home diagnostic platform ("Virex Technology").Virex Technology, invented and developed by Boston University (BU) Professors Mark Grinstaff and Scott Schaus and Virex scientists, employs widely used electrochemistry found in household diabetes glucometer devices for next generation diagnostics.Virex Technology has demonstrated extremely high sensitivity for multiple biological analytes including COVID-19 virus detection as sensitive as 10 TCID50, rivalling PCR sensitivity.Virex's early liver cancer biomarker test detects a liver cancer biomarker in as little as 2 microliters of blood.Vir
Executed binding term sheet with Sorrento Therapeutics (NASDAQ:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidateNew collaboration with India's Syngene International to develop a COVID-19 vaccine candidateNew co-development collaboration with South Africa's Rubic consortium to establish a basis for researching, developing, and manufacturing multiple other C1 produced vaccines in addition to DYAI-100Potential to support vaccine production for up to 100% of the world's populationDyadic's C1 productio
AMONG MULTIPLE CLINICAL- AND PRECLINICAL-STAGE NCE (NEW CHEMICAL ENTITY) COMPOUNDS ACQUIRED, ABIVERTINIB IS AN ANCHORING LATE-STAGE DRUG PRODUCT WITH POSITIVE CLINICAL TRIAL RESULTS IN BOTH NON-SMALL CELL LUNG CANCER (NSCLC) AND B-CELL LYMPHOMA: Abivertinib is potentially one of the most effective clinical-stage dual tyrosine kinase inhibitors (TKI), targeting both mutant epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).Abivertinib is a pyrrolopyrimidine-based irreversible third-generation (3G) EGFR TKI, structurally distinct from all other 3G pyrimidine-based EGFR inhibitors.More than 600 cancer patients have been treated with Abivertinib with a strong safety profi
PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp
SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, as Covid-19 special consultant to Sorrento's Chairman and CEO Henry Ji. Governor Thompson's appointment is effective immediately. Most recently, Thompson served as the President of the University of Wisconsin System from July 2020 through March 2022, one of the largest
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of former Roche Laboratories executive, Tammy Reilly, to Sorrento's board of directors. Ms. Reilly brings more than 30 years of life science, big pharma and operating leadership experience within healthcare therapeutics, consumer merchandising and healthcare diagnostic companies to Sorrento. "Sorrento continues to strengthen its already experienced board of directors," said Henry Ji, Ph.D., Chairman and Chief Executive O
SAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), who is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that Elizabeth Czerepak will join the company as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective May 18, 2022. Ms. Czerepak will be a member of the Scilex and Sorrento Executive Leadership Teams, reporting to Scilex's Chief Executive Officer and President, Jaisim Shah, and Sorr
PALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors. Ms. Hamill brings to the Scilex board more than three decades of experience in the biopharma industry, serving most recently as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc. Prior to
Columbus, Ohio, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) ("Better For You Wellness" or the "Company"), an Ohio-based blank check company, is pleased to announce that it has appointed five independent non-executive directors to its Board of Directors including Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD (the "New Directors"). All five New Directors have been appointed for initial terms of 2 years, and Better For You Wellness, Inc.'s seven member Board of Directors is now composed of a majority of Independent Directors demonstrating the Company's focus on governance
4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
5 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)
Gainers TransMedics Group (NASDAQ:TMDX) stock moved upwards by 10.2% to $71.15 during Wednesday's after-market session. The market value of their outstanding shares is at $2.2 billion. As per the news, the Q4 earnings report came out today. AquaBounty Technologies (NASDAQ:AQB) shares rose 6.32% to $0.84. The company's market cap stands at $59.7 million. BioVie (NASDAQ:BIVI) stock increased by 5.83% to $5.99. The market value of their outstanding shares is at $209.5 million. Infinity Pharmaceuticals (NASDAQ:INFI) stock moved upwards by 5.45% to $0.58. The company's market cap stands at $51.8 million. Tivic Health Systems (NASDAQ:TIVC) shares rose 5.02% to $0.23. The market value of their
Gainers Windtree Therapeutics Inc (NASDAQ:WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous Formulation For The Treatment Of Acute Heart Failure." ECARX Holdings Inc. (NASDAQ:ECX) gained 68% to $5.71. Terran Orbital Corporation (NYSE:LLAP) surged 52% to $2.60 after the company annonced it has been awareded a $2.4 billion contract to design, build, and deploy 300 satellites for Rivada Space Networks. Hoth Therapeutics Inc (NASDAQ:HOTH) shares rose 34.3% to $2.6613 after dropping over 9% on Tuesday. Hoth Therapeutics recently entered into a service agreement with Shareholder Intelligence Se
Gilead Sciences Inc (NASDAQ:GILD) announced data from three retrospective real-world Veklury (remdesivir) studies for COVID-19 treatment. The studies demonstrated that initiating Veklury within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity. A reduction in mortality was also observed in vulnerable populations. Related: WHO Recommends Gilead's COVID-19 Therapy For Severe Disease. Two studies analyzed clinical practice information from the U.S. Premier Healthcare databases of more than 500,000 adult patients hospitalized with COVID-19. For patients with no do
Sorrento Therapeutics Inc (NASDAQ:SRNE) announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners. The financing will provide Sorrento with immediate liquidity to continue operating its business as usual during its chapter 11 case. A hearing for final financing approval is currently set for March 29, 2023. Related: Sorrento Therapeutics Stock Nosedives After Filing Bankruptcy Paperwork. As of its chapter 11 filing, Sorrento had over approximately $1 billion in assets. Scilex Holding Company, majority-owned by Sorrento, is not a debtor in Sorrento's chapter 1
Sorrento Therapeutics Inc (NASDAQ:SRNE) shares are rising on Wednesday after the U.S. Bankruptcy Court granted interim approval of the company's $75 million debtor-in-possession financing. What To Know: The financing approval comes in connection with Sorrento's bankruptcy filling, which took place on Feb. 13 when Sorrento and its subsidiary, Scintilla Pharmaceuticals, commenced voluntary proceedings under chapter 11. The financing will provide Sorrento with immediate liquidity so it will be able to continue operating its business as usual during its chapter 11 case. A hearing for final approval of the financing is currently expected to take place on March 29. "We are pleased to have recei
Gainers Windtree Therapeutics (NASDAQ:WINT) stock increased by 28.8% to $0.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $9.5 million. Sorrento Therapeutics (NASDAQ:SRNE) shares moved upwards by 24.8% to $0.48. The market value of their outstanding shares is at $263.5 million. MediciNova (NASDAQ:MNOV) stock increased by 16.52% to $2.68. The market value of their outstanding shares is at $131.4 million. Cognition Therapeutics (NASDAQ:CGTX) shares moved upwards by 16.2% to $1.9. The company's market cap stands at $55.0 million. Immix Biopharma (NASDAQ:IMMX) stock rose 15.45% to $2.39. The company's market cap stands at $33.2 million. Spruce
Gainers Windtree Therapeutics Inc (NASDAQ:WINT) shares rose 65.3% to $0.28 in pre-market trading. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous Formulation For The Treatment Of Acute Heart Failure." Cyren Ltd (NASDAQ:CYRN) rose 50.2% to $0.62 in pre-market trading after the company reported non-binding LOI to sell Iceland-based anti-malware business assets. Sorrento Therapeutics Inc (NASDAQ:SRNE) rose 44.4% to $0.56 in pre-market trading after the company received court approval for $75 million financing in Chapter 11 case. Wag! Group Co (NASDAQ:PET) rose 21.7% to $2.80 in pre-market trading after the company posted bette
Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , ))))), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento's chapter 11 case, which was filed on February 13, 2023. The financing will provide Sorrento with immediate liquidity so that it can continue operating its business as usual during its chapter 11 case. A hearing for final approval of the financing is currently set fo
Gainers Arbe Robotics Ltd. (NASDAQ:ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. Ambrx Biopharma Inc. (NYSE:AMAM) surged 59% to $5.17. Ambrx Biopharma recently announced initial data from its ongoing Phase 1 APEX-01 trial of ARX517, Ambrx's proprietary anti-PSMA ADC, in prostate cancer patients. Harbor Custom Development, Inc. (NASDAQ:HCDI) shares jumped 50.3% to $0.5260 after the company said it has contracted to sell mills Crossing townhomes for $14.25 million. Mobilicom Limited (NASDAQ:MOB) shares gained 37.4% to $2.1307 after the company announced it has entered a strategic partnership wi